Skip to main content
. 2016 Jan 19;34(7):747–755. doi: 10.1200/JCO.2015.62.6846

Fig 3.

Fig 3.

Association of CD33 levels and GO response by treatment arm and risk group. Relapse risk from complete remission by treatment arm. (A) Low-risk patients with low CD33 expression (Q1). (B) Low-risk patients with high CD33 expression (Q2 to Q4). (C) Intermediate-risk patients with low CD33 expression (Q1). (D) Intermediate-risk patients with high CD33 expression (Q2 to Q4). (E) High-risk patients with low CD33 expression (Q1). (F) High-risk patients with high CD33 expression (Q2 to Q4). GO, gemtuzumab ozogamicin; Q, quartile.